Borje Andersson
Follow
Get notifications in MyBN when activity occurs.
Borje Andersson
Chief Medical Officer / Race Oncology
Professor Borje Andersson was initially engaged as a scientific and clinical consultant to Race Oncology in January 2019, before becoming chair of its clinical advisory board in December 2019 and chief medical officer in October 2020.
Prof Andersson is a research leader in the field of leukaemia and stem cell transplantation at the MD Anderson Cancer Center in Houston, Texas. He is the inventor of IV Busulfan, an FDA-approved drug used in stem cell transplantation.
Prof Andersson is a research leader in the field of leukaemia and stem cell transplantation at the MD Anderson Cancer Center in Houston, Texas. He is the inventor of IV Busulfan, an FDA-approved drug used in stem cell transplantation.
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 287th | Race Oncology | 57% | 62% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Race Oncology | $4.0m |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEW ROLE: Chief Medical Officer, Race Oncology | 16 Apr 2021 |
| NEW ROLE: Executive Director, Race Oncology | 03 Nov 2020 |
